NRXP — NRX Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1719406 ·
Last close
$2.89
Market Cap
$125.12M
52W High
$5.05
52W Low
$1.62
ADV30
628,995
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,101,000 | 426,000 | -6,501,000 | -16,520,000 | 34,160,000 | 26,686,000 | 34,330,000 |
| Mar 2026 | 1,068,000 | 437,000 | -4,748,000 | -1,430,000 | 11,903,000 | 6,713,000 | 25,719,000 |
| Dec 2025 | 983,000 | 575,000 | -4,624,000 | 360,000 | 12,956,000 | 7,797,000 | 28,893,000 |
| Sep 2025 | 242,000 | 145,000 | -4,024,000 | -5,890,000 | 14,996,000 | 7,184,000 | 40,751,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,927,000
Investing CF
$-462,000
Financing CF
$19,115,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.63
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-308,325,000
Inventory
—
Receivables
$181,000
ST Investments
—
EBIT TTM
$-23,637,000
Pretax Income TTM
$-24,541,000
Interest Exp TTM
$904,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,394,000
EBITDA
$-19,762,000
Free Cash Flow
$-9,639,625
Enterprise Value
$121,241,768
Total Cash
$26,686,000
Total Debt
$834,000
Shares Out
43,295,767
Trailing EPS
$-0.51
Book Value
$-0.00
ROE
—
ROA
-64.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,225,000 | -16,224,000 | -28,622,000 | 12,956,000 | 28,893,000 | -15,937,000 | -14,112,000 |
| Dec 2024 | 0 | -18,502,000 | -25,126,000 | 3,651,000 | 26,874,000 | -23,223,000 | -10,637,000 |
| Dec 2023 | 0 | -27,587,000 | -30,150,000 | 7,315,000 | 19,048,000 | -11,733,000 | -21,657,000 |
| Dec 2022 | 0 | -44,335,000 | -39,754,000 | 25,816,000 | 18,407,000 | 7,409,000 | -39,755,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$2,293,000
NetIncome TTM
$-24,540,000
OpCashFlow TTM
—
Assets (Latest)
$11,903,000
Forward EPS
$0.50
Max Pain — expiry 2026-12-18
max pain strike: $2.50 · spot: $2.89 · call oi: 6,113 · put oi: 279
Expected Move to 2026-12-18:
±$1.02
(35.29%) —
implied range
$1.87 –
$3.91
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp. | $124.86M | $7.28 | — |
| HURA | TuHURA Biosciences, Inc./NV | $122.99M | $1.93 | — |
| SPRB | SPRUCE BIOSCIENCES, INC. | $130.88M | $45.54 | — |
| VTVT | vTv Therapeutics Inc. | $118.93M | $30.08 | — |
| DERM | Journey Medical Corp | $132.24M | $5.95 | — |
News headlines (Yahoo Finance, 1h cache)
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
2026-09-15 19:11 · Yahoo
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
2026-09-14 11:00 · Yahoo
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-09-08 11:00 · Yahoo
NRX Pharmaceuticals Inc (NRXP) (Q2 2026) Earnings Call Highlights: Advancing Ketamine Pipeline ...
2026-08-18 05:02 · Yahoo
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
2026-08-17 11:00 · Yahoo
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates
2026-08-15 00:15 · Yahoo
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
2026-08-10 14:04 · Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
2026-08-07 20:01 · Yahoo
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
2026-06-25 20:01 · Yahoo
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
2026-06-25 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.